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Aim: There are limited data on the feasibility of programmed death ligand-1 (PD-L1) expression as a prog-
nostic biomarker in metastatic angiosarcoma. Patients & methods: We retrospectively collected and an-
alyzed the data on PD-L1 expression in 70 angiosarcoma patients who were diagnosed at our center
between 2005 and 2019. Results: Thirteen (19%) patients had PD-L1 expression. Metastatic angiosar-
coma patients who were PD-L1-negative (n = 24) showed longer median progression-free survival (4.9
vs 1.6 months; p = 0.04) and median overall survival (OS; 10.9 vs 5.4 months; p = 0.01) than those who
were PD-L1-positive (n = 4). PD-L1 status proved to be a significant factor for OS. Conclusion: Metastatic
angiosarcoma patients with PD-L1 expression showed shorter survival. PD-L1 status is an independent
prognostic factor for OS in metastatic angiosarcoma patients.
Lay abstract: Angiosarcoma, a rare subtype of sarcoma, is highly aggressive and has poor prognosis. The
majority of patients are diagnosed at advanced and metastatic stages, and treatment options for these
subsets of patients are limited to cytotoxic chemotherapy. Validation of prognostic markers including PD-
L1 expression remain to be fully carried out in metastatic angiosarcoma. In our study, we assessed the
PD-L1 expression in metastatic angiosarcoma and its role as a prognostic biomarker.
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Angiosarcoma, which originates from lymphatic endothelial cells of the blood vessels, is a rare subtype of soft tissue
sarcoma (STS) [1]. STS accounts for less than 1% of all adult malignancies, and angiosarcoma accounts for less
than 1% of all STS subtypes [2,3]. Angiosarcoma mainly affects adults and elderly patients and can manifest in
any anatomic site in any part of the body, including cutaneous lesions, which account for 60% of all cases [4,5].
Angiosarcoma is highly aggressive and is associated with poor prognosis, with a median overall survival (mOS) of
6–16 months [6]. Among patients with angiosarcoma, 20–30% of patients are initially diagnosed in the metastatic
setting, and approximately 50% of the patients with localized disease experience disease progression [7–9].
A few cytotoxic chemotherapeutic drugs are effective against metastatic angiosarcoma, such as anthracycline, tax-
ane and pazopanib. Anthracycline-based chemotherapy, in combination with ifosfamide, as the first-line treatment
for angiosarcoma showed similar outcomes to those who had received first-line treatment against other STSs, with
improved progression-free survival (PFS) [10]. In contrast with other subtypes of STS, angiosarcoma is sensitive to
taxane as the first- or second-line treatment [11–13]. Pazopanib, a multitarget tyrosine kinase inhibitor, as second- or
later-line therapy also showed improvement in PFS, but no benefit in overall survival (OS) [14]. The rarity and poor
prognosis of angiosarcoma further limit prospective trials necessary for the development of treatment options.
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Recently, anti-programmed death-1 (anti-PD-1) inhibitors such as pembrolizumab and nivolumab showed the
modest clinical activity in the subset of advanced STS [15,16]. However, angiosarcoma patients were not enrolled in
the SARC028 trial, and only three patients were evaluated in the nivolumab and ipilimumab group in the Alliance
A091401 trial. There is limited evidence on the clinical implications of PD-L1 in angiosarcoma. Thus, our study
aimed to investigate PD-L1 expression in metastatic angiosarcoma and evaluate its clinical relevance. In addition,
we evaluated the feasibility of PD-L1 expression as a prognostic biomarker that could aid in the design of effective
STS treatments.
Patients & methods
Study design & patient selection
We collected data from 70 angiosarcoma patients diagnosed from 2005 to 2019 in a single center. The key inclusion
criteria included: pathologically confirmed angiosarcoma; formalin-fixed, paraffin-embedded (FFPE) tissue blocks
available for the examination of PD-L1 expression; and complete medical history records that included last follow-up
or death date.
FFPE tissue blocks were collected from surgical or biopsied specimens, which were performed at baseline or
after recurrence. All hematoxylin and eosin (H&E)-stained slides were reviewed by one pathologist (SH Kim),
and the clinical data were obtained following a review of the medical records. Clinicopathological variables such as
age, sex, tumor location, differentiation, status of resection margin, initial presentation of the disease and palliative
chemotherapy were retrospectively reviewed. Tumor location was divided into four categories consisting of the
head and neck, thorax, abdomen and extremity. Histology included well-differentiated angiosarcoma, spindle cell
angiosarcoma, epithelioid angiosarcoma and poorly differentiated angiosarcoma. The 8th edition of the American
Joint Committee on Cancer guideline of tumor, node and metastasis (TNM) classification was used for determining
cancer stage [17].
Tissue selection, immunohistochemistry staining & assessment
The H&E-stained slides were examined, and one or two representative FFPE archival blocks were selected for
each case. Immunohistochemical staining was performed using PD-L1 monoclonal antibody, Clone 22C3 (Agilent
Technologies, CA, USA/Dako, CA, USA) and the DAKO Link 48 system (Agilent, CA, USA). After deparaf-
finization, heat-induced antigen retrieval was performed using EnVision™ FLEX Target Retrieval Solution, Low
pH (Dako Omnis). Positive rate for PD-L1 was scored by an experienced pathologist (SH Kim). We analyzed
the combined positive score (CPS) and tumor proportion score of the PD-L1-immunostained slides. Tumor cell
positivity includes partial and complete linear membrane staining at any intensity. Immune cell positivity includes
cytomembranous expression of lymphocytes and macrophages. CPS was defined as the number of PD-L1-positive
cells (tumor cells, macrophages, lymphocytes) divided by the total number of tumor cells and multiplied by 100 [18].
PD-L1 positivity was defined as CPS ≥1.
Statistical analysis
Statistical analysis was performed using SPSS, version 25 (IBM, IL, USA), and GraphPad Prism 8.0 software
(GraphPad Software, Inc., CA, USA). The correlations between the variables were analyzed using the Fisher’s
exact test for categorical variables and the sample t-test for continuous variables. We used the Kaplan–Meier
method for calculating OS and PFS [19]. The overall response rate was calculated as the percentage of patients
experiencing a confirmed complete response or partial response as per the Response Evaluation Criteria in Solid
Tumors (RECIST) 1.1 guidelines. PFS was defined as the time from the start of first-line palliative chemotherapy
to the date of progression or death. OS was defined as the period from the diagnosis of metastatic or recurrent
angiosarcoma until the date of the last follow-up or death. Cox regression was used for the multivariate analysis of
OS. Statistical analysis was two-sided, with a p-value of less than 0.05 considered statistically significant.
Results
Patient characteristics
Table 1 summarizes the clinicopathological characteristics of the 70 angiosarcoma patients according to the PD-L1
status (CPS ≥1). The male-to-female ratio was 1.33, and the median patient age was 61 years (range: 7–86 years).
The most common tumor location was the head and neck (n = 28, 40%), followed by the abdomen (n = 18, 26%),
thorax (n = 15, 21%) and extremity (n = 9, 13%). Most of the patients were diagnosed with well-differentiated
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Table 1. Baseline characteristics of all patients.
Variables PD-L1 expression
Total
n = 70 (%)
CPS <1
n = 57 (81%)
CPS ≥1
n = 13 (19%)
p-value
Sex Male 40 (57%) 35 (87%) 5 (13%) 0.21
Female 30 (43%) 22 (73%) 8 (27%)
Median age, years (range) 61 (7–86) 61 (7–86) 59 (25–84)
Median tumor size, cm (range) 4 (0.3–99) 4 (0.3–99) 5 (0.7–61)
Tumor location Head and neck 28 (40%) 21 (75%) 7 (25%) 0.45
Thorax 15 (21%) 14 (93%) 1 (7%)
Abdomen 18 (26%) 14 (78%) 4 (22%)
Extremity 9 (13%) 8 (89%) 1 (11%)
Histology Well differentiated 29 (41%) 28 (97%) 1 (3%) 0.01
Spindle 14 (20%) 13 (93%) 1 (7%)
Epithelioid 3 (5%) 0 (0%) 3 (100%)
Poorly differentiated 24 (34%) 16 (67%) 8 (33%)
Initial distant metastasis No 42 (60%) 33 (79%) 9 (21%) 0.54
Yes 28 (40%) 24 (86%) 4 (14%)
Surgery No 29 (41%) 26 (90%) 3 (10%) 0.21
Yes 41 (59%) 31 (76%) 10 (24%)
Resection margin† Negative 43 (61%) 36 (84%) 7 (16%) 0.99
Positive 21 (30%) 18 (86%) 3 (14%)
Definitive radiotherapy No 59 (84%) 48 (81%) 11 (19%) 0.99
Yes 11 (16%) 9 (82%) 2 (18%)
Adjuvant chemotherapy No 64 (91%) 52 (81%) 12 (19%) 0.99
Yes 6 (9%) 5 (63%) 1 (17%)
Adjuvant radiotherapy No 51 (73%) 43 (84%) 8 (16%) 0.32
Yes 19 (27%) 14 (74%) 5 (26%)
Palliative chemotherapy No 26 (37%) 20 (77%) 6 (23%) 0.53
Yes 44 (63%) 37 (84%) 7 (16%)
Palliative radiotherapy No 43 (61%) 34 (79%) 9 (21%) 0.75
Yes 27 (39%) 23 (85%) 4 (15%)
First-line chemotherapy‡ Paclitaxel 31 (44%) 25 (81%) 6 (19%) 0.85
Pazopanib 3 (5%) 2 (67%) 1 (33%)
Others 10 (14%) 8 (80%) 2 (20%)
†Resection margin data were not available for six patients.
‡Twenty-six patients (37%) did not receive palliative chemotherapy.
CPS: Combined positive score; PD-L1: Programmed death ligand-1.
angiosarcoma (n = 29, 41%) and poorly differentiated angiosarcoma (n = 24, 34%). Other histology subtypes
included spindle (n = 14, 20%) and epithelioid angiosarcoma (n = 3, 5%). For patients who underwent surgery
(n = 41, 59%), most had negative resection margins (n = 43, 61%). Among these patients, six (9%) received
adjuvant chemotherapy and 19 (27%) were treated with adjuvant radiotherapy.
Twenty-eight patients (40%) were initially diagnosed with distant metastasis, and 44 metastatic and recurrent
patients (67%) received palliative systemic chemotherapy. Most patients received paclitaxel (n = 31, 44%), followed
by other regimens (n = 10, 14%) and pazopanib (n = 3, 5%). Other regimens that were administered included
adriamycin and ifosfamide (n = 4); ifosfamide (n = 1); doxorubicin and olaparib (n = 1); mesna, doxorubicin,
ifosfamide and dacarbazine (n = 1); etoposide, ifosfamide, cisplatin (n = 1); etoposide and cisplatin (n = 1); and
vincristine, cyclophosphamide and doxorubicin alternatively followed by the ifosfamide and etoposide regimen
(n = 1).
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Figure 1. H&E staining and IHC of PD-L1 expression in angiosarcoma. H&E staining (×200) and IHC (×200) of PD-L1
expression in angiosarcoma patients according to (A) PD-L1-negative angiosarcoma and (B) PD-L1-positive epithelioid
angiosarcoma.
CPS: Combined positive score; H&E: Hematoxylin and eosin; IHC: Immunohistochemistry; PD-L1: Programmed death
ligand-1.
PD-L1 expression status & clinicopathological features
We explored the correlation between PD-L1 expression (CPS ≥1) and clinicopathological features. Among 70
patients, 13 (19%) were positive for PD-L1 expression. There was a significant difference in histology (p = 0.01)
between the PD-L1-positive and -negative groups. In the PD-L1-positive group, nine of 13 patients (19%) were
categorized as poorly differentiated. The remaining patients included well-differentiated (n = 1), spindle (n = 1) and
epithelioid (n = 3) angiosarcoma. Notably, all three cases of epithelioid angiosarcoma patients showed high levels
of PD-L1 expression, with CPS ≥50 (Figure 1). This is in stark contrast to the result in the PD-L1-negative group,
which included a considerable number of patients with well-differentiated (n = 28, 97%) and spindle angiosarcomas
(n = 13, 93%). Other factors such as sex, tumor location, histology, initial distant metastasis, surgery, resection
margin, definitive radiotherapy, adjuvant chemotherapy, adjuvant radiotherapy, palliative chemotherapy, palliative
radiotherapy and first-line regimen were not significantly different between the two groups. In addition, we
investigated whether clinicopathological features differed according to different CPS cutoffs (10, 50) and tumor
proportion score (1, 10, 50) (Supplementary Tables 1 & 2). Among the patients who were both diagnosed
initially with metastatic angiosarcoma and received palliative systemic chemotherapy (n = 23), there were four
PD-L1-positive patients (Figure 2).
Patients’ PD-L1 expression was positive with CPS of 100, 5, 60 and 90, in the order delineated in the Swimmer
plot. One of these patients who was diagnosed with epithelioid angiosarcoma received doxorubicin and olaratumab.
Three other patients with poorly differentiated pathology received paclitaxel as the first-line treatment. These
patients showed rapid progression. The remaining 19 patients with no PD-L1 expression showed variable responses
to first-line chemotherapeutic agents.
Survival outcome according to PD-L1 expression
There was no significant difference in median PFS (mPFS) of both recurrent and metastatic angiosarcoma patients
(n = 44) and the mOS of the total patient population (n = 70) (Supplementary Figure 1). We also analyzed the
clinical relevance of PD-L1 expression in this subset of patients who received palliative chemotherapy (n = 23) and
found that the PD-L1-negative patients (n = 19) had longer mPFS and mOS than PD-L1-positive patients (n = 4)
(Figure 3A). The mPFS were 4.9 and 1.6 months (hazard ratio [HR]: 0.32; 95% CI: 0.11–0.95) in PD-L1-negative
and PD-L1-positive patients, respectively (p = 0.04). The median OS was 10.9 months for PD-L1-negative patients
and 5.4 months (HR: 0.26; 95% CI: 0.09–0.77; p = 0.01) for PD-L1-positive patients (Figure 3B).
10.2144/fsoa-2020-0211 Future Sci. OA (2021) FSO691 future science group











































Figure 2. Swimmer plot for initial metastatic angiosarcoma patients treated with palliative chemotherapy (n = 23). Each patient’s initial
treatment is described in the left column. Other regimens include ifosfamide (n = 1); doxorubicin and olaparib (n = 1); mesna, doxorubicin,
ifosfamide and dacarbazine (n = 1); etoposide, ifosfamide and cisplatin (n = 1); vincristine, cyclophosphamide and doxorubicin
alternatively followed by ifosfamide and etoposide (n = 1).
AI: Adriamycin and ifosfamide; CPS: Combined proportion score; PD-L1: Programmed death ligand-1; PFS: Progression-free survival.
Median PFS:
4.9 (CPS <1) vs 1.6 months (CPS ≥1)
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Figure 3. Survival analysis of initial metastatic angiosarcoma patients (n = 28) with combined positive score ≥1.
Kaplan–Meier estimates of (A) PFS (n = 23) and (B) OS (n = 28).
CPS: Combined positive score; HR: Hazard ratio; OS: Overall survival; PFS: Progression-free survival.
future science group 10.2144/fsoa-2020-0211
Research Article Lee, Ahn, Kim et al.
Median PFS:
7.9 (CPS <1) vs 2.1 months (CPS ≥1)
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Figure 4. Survival analysis of initial metastatic angiosarcoma patients treated with paclitaxel with a combined
positive score of 1 (n = 12) or higher (n = 3). Kaplan–Meier estimates of (A) PFS and (B) OS.
CPS: Combined positive score; HR: Hazard ratio; OS: Overall survival; PFS: Progression-free survival.
Table 2. Univariate and multivariate analyses of overall survival in initial metastatic angiosarcoma patients (n = 28).
Variables Univariate Multivariate
OS (months) p-value HR (95% CI) p-value
Sex (male vs female) 10.9 vs 9.4 0.69
Age (≥20 vs 20 years) 8.2 vs 10.9 0.27
Tumor size (≥5 cm vs 5 cm) 7.2 vs 11.3 0.12
Histology (spindle vs others†) 10.5 vs 8.2 0.09
PD-L1 status (CPS 1 vs ≥1) 2.3 vs 10.9 0.01 7.62 (1.73–33.5) 0.01
Tumor location (axial vs extremity) 9.4 vs 13.6 0.54
Surgery (yes vs no) 10.9 vs 7.6 0.20
Margin status (positive vs negative) Not reached vs 7.6 0.01 0.05 (0–1.25) 0.07
Palliative chemotherapy (yes vs no) 8.2 vs 30 0.33
†Others: well differentiated (n = 8), poorly differentiated (n = 11), epithelioid (n = 1).
CPS: Combined positive score; HR: Hazard ratio; OS: Overall survival; PD-L1: Programmed death ligand-1.
Regarding treatment efficacy, we further analyzed the prognostic value of PD-L1 expression for patients who
received paclitaxel as first-line palliative treatment. Among the 15 cases, PD-L1 expression was positive in 12
patients (80%) and negative in three patients (20%). mPFS were 7.9 and 2.1 months in the PD-L1-negative and
PD-L1-positive groups, respectively (HR: 0.27; 95% CI: 0.07–1.00; p = 0.06) (Figure 4A). Although there was a
trend for longer PFS in the PD-L1-negative angiosarcoma patients treated with paclitaxel, the difference was not
statistically significant. mOS was 10.7 months for PD-L1-negative patients and 3.3 months for PD-L1-positive
patients (HR: 0.31; 95% CI: 0.08–1.12; p = 0.01) (Figure 4B).
In univariate analysis, the PD-L1 status (p = 0.01) and margin status (p = 0.01) were associated with OS in
initially metastatic angiosarcoma patients (n = 28) (Table 2). However, sex, age, tumor size, histology, tumor
location (axial vs extremity), surgery and palliative chemotherapy were not associated with OS. In multivariate
analysis, only the PD-L1 status (HR: 7.62; 95% CI: 1.73–33.5; p = 0.01) remained significant, whereas the margin
status was not associated with OS.
Discussion
In our study, we retrospectively examined 70 angiosarcoma patients diagnosed at our cancer center. We selected 28
patients with initial metastatic angiosarcoma, and analyzed the clinical relevance of PD-L1 expression with CPS
≥1. Patients with PD-L1 expressions had worse mPFS and mOS than those with negative PD-L1 expressions.
Notably, the patients who progressed in the metastatic setting had strong PD-L1 expression. All three epithelioid
10.2144/fsoa-2020-0211 Future Sci. OA (2021) FSO691 future science group
PD-L1 expression in angiosarcoma Research Article
angiosarcoma patients had high levels of PD-L1 expression with CPS ≥50. Comprehensive characterization of
PD-L1-positive epithelioid angiosarcoma is warranted in a larger cohort to validate whether this particular subset
of patients has worse prognosis.
Angiosarcoma is highly aggressive and a rare type of tumor. It is highly underrepresented even within other
STSs, and the heterogeneity with different pathologic subtypes and the wide range of clinicopathological and
genomic complexities further limit treatment options and opportunities for clinical studies [20]. There are few
publications that have addressed the prognostic role of PD-L1 expression in STS [21–28]. These studies were based
on immunohistochemistry (IHC) on tissue microarrays or slides, all of which used different scoring systems and
definitions of PD-L1-positive expression. Two studies defined PD-L1 expression as PD-L1 detected in ≥5% of
tumor cells [24,28]. In a retrospective study of cutaneous angiosarcoma of 52 patients, PD-L1 was defined in
semiquantitative manner, with tumors with score >2 (PD-L1: 5–10%) graded as positive [26]. Another study
analyzed PD-L1 mRNA expression in 470 patients and defined low and high PD-L1 expression using a receiver
operating characteristic curve for determining the cutoff value [23]. Only a few angiosarcoma patients were evaluated
in these studies, and the discrepancies and variabilities in the PD-L1 assay made it difficult to determine PD-L1
expression as a prognostic biomarker, especially for the subset of angiosarcoma patients. Overall, results of the role
of PD-L1 as prognostic marker in metastatic angiosarcoma were conflicting. Some studies showed that PD-L1
expression was associated with poor prognosis [21,23,26,27], while one study of cutaneous angiosarcoma with PD-L1
expressions had favorable survival in stage I [28]. Other studies concluded that there were no correlations [24,25].
Recently, studies were conducted for assessing the impact of different IHC platforms and the cutoff value for
PD-L1 expression in multiple tumors [29,30]. In our study, we used standardized IHC criteria for PD-L1 expression.
PD-L1, clone 22C3 (Dako, CA, USA), was used as the primary antibody and defined PD-L1 expression as CPS
≥1. Similar to our results, tumors with high levels of PD-L1 expression have shown worse survival [22,31–33].
Immune evasion is one of the hallmarks of cancer, and PD-L1 is the key immune checkpoints that orchestrates
immune escape and prevents antitumor immune responses, especially during the maintenance of peripheral tol-
erance [34]. Thus, novel therapies such as those targeting the PD-1/PD-L1 axis have gained wide recognition for
treating solid tumors to overcome the immune suppressive environment [35]. Currently, the paradigm has shifted
from chemotherapy and targeted agents to immunotherapies in several tumors [36,37]. Anti-PD-L1 agents such as
pembrolizumab and nivolumab have also been studied in metastatic STS [15,16]. With the exception of that in
undifferentiated pleomorphic sarcoma or dedifferentiated liposarcoma, pembrolizumab failed to meet its primary
end point of objective response [16]. Nivolumab monotherapy also failed to show clinical benefit in STS patients [15].
Of note, none of the patients with metastatic angiosarcomas were enrolled in either pembrolizumab or nivolumab
monotherapy. However, three angiosarcoma patients were enrolled in the nivolumab and ipilimumab combination
group, and the mOS of 42 patients with a different histology was 14 months (95% CI: 9.6–not reached), which is
comparable to that of patients treated with chemotherapy agents [38,39].
To overcome the limitation of anti-PD-L1 monotherapy, combination treatments with chemotherapy may
be a possible option for metastatic STS, including angiosarcoma. Certainly, platinum-based chemotherapy with
pembrolizumab has improved the efficacy in non-small-cell lung cancers, and this combination is also being tested
for other solid tumors [40–42]. The efficacy of durvalumab with doxorubicin as the first-line treatment in STS is
currently under investigation at our center (ClinicalTrials.gov Identifier: NCT03802071).
The main limitations of this study were its use of retrospective data and a small sample size owing to the
rarity of angiosarcoma cases. Even though we collected a large cohort of angiosarcoma patients, only 40% were
initially diagnosed in the metastatic setting and a third of them received palliative chemotherapies. Since there were
only significant outcomes for the initially metastatic patients, we excluded recurrent patients who also received
chemotherapies, thus further limiting the sample size for the validation of PD-L1 as a prognostic factor for
angiosarcoma. Therefore, the prognostic role of PD-L1 should be investigated in larger angiosarcoma cohorts.
Conclusion
Patients initially diagnosed with metastatic angiosarcoma expressing PD-L1 by CPS ≥1 had shorter mPFS and
mOS, and multivariate analysis showed that PD-L1 is an independent prognostic factor for OS. A larger number of
patients should be recruited in a prospective manner for prognostic validation of PD-L1 in metastatic angiosarcoma.
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Future perspective
Metastatic angiosarcoma has poor prognosis, and identifying prognostic markers may provide better treatment
options in the future. Retrospective analysis of the patients in metastatic settings with high PD-L1 by CPS ≥1
had shorter OS, thus supporting the validation of PD-L1 as an independent prognostic marker. Our results are
stepping stones for future studies exploring the PD-L1 expression as a useful prognostic tool in angiosarcoma.
Summary points
• We investigated the feasibility of using programmed death ligand-1 (PD-L1) expression as a prognostic biomarker
in metastatic angiosarcoma patients.
• We retrospectively examined 70 angiosarcoma patients who were diagnosed at our center between 2005 and
2019.
• We then selected 28 patients with initial metastatic angiosarcoma to analyze the clinical relevance of PD-L1
expression with combined positive score (CPS) ≥1.
• Among metastatic angiosarcoma patients (n = 28), PD-L1-negative patients (n = 24) showed longer median
progression-free survival (4.9 vs 1.6 months; p = 0.04) and median overall survival (10.9 vs 5.4 months; p = 0.01)
than PD-L1-positive patients (n = 4).
• Multivariate analysis showed PD-L1 status as a significant factor for overall survival in metastatic angiosarcoma
patients.
• Swimmer plot showed that all three epithelioid angiosarcoma patients had high expression levels of PD-L1 with
CPS ≥50. Further characterization of PD-L1-positive epithelioid angiosarcoma is warranted in a larger prospective
cohort.
• Our findings suggest that the assessment of PD-L1 expression as a diagnostic and therapeutic strategy could be
implemented in metastatic angiosarcoma.
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